- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17.12.25 | Harbour BioMed docks with BMS in antibody discovery, development deal worth up to $1.1B | ||
| 17.12.25 | Addition Tx does the math and emerges from stealth with $100M, biotech vets on exec team | ||
| 16.12.25 | Nektar claims phase 2 alopecia success after excluding patients who 'should never have been enrolled' | ||
| 16.12.25 | Aldeyra dry eye disease candidate hit by FDA delay amid shifting agency guidance, biotech says | ||
| 16.12.25 | Xoma acquires another struggling biotech, this time zeroing in on Generation Bio | ||
| 16.12.25 | December deal flurry rolls on with Genentech-Caris cancer collab worth up to $1.1B | ||
| 16.12.25 | Yarrow blooms with $1.37B deal, landing autoimmune thyroid disease drug from China's GenSci | ||
| 15.12.25 | Aviceda geographic atrophy hopeful fails to top Astellas med in phase 2 | ||
| 15.12.25 | J&J-backed Link launches with $60M, plan to create next-gen CAR-T therapies | ||
| 15.12.25 | Pfizer, Sanofi pull out checkbooks for separate year-end autoimmune pacts | ||
| 15.12.25 | Immunome's desmoid tumor treatment triumphs in phase 3, setting up approval filing | ||
| 15.12.25 | Chai infuses AI drug discovery efforts with $130M series B | ||
| 15.12.25 | Kyverna gains clear view to first CAR-T approval for autoimmune disease after 'truly remarkable' SPS readout | ||
| 15.12.25 | Sanofi's tolebrutinib woes pile up with FDA delay, trial miss | ||
| 15.12.25 | Sobi pays $950M upfront to snap up phase 3 gout specialist Arthrosi Therapeutics | ||
| 12.12.25 | Obesity biotech Zealand seeks partners to 'take therapies directly to the brain' | ||
| 12.12.25 | 2026 outlook: Biotech poised to outperform bear markets of '21-24, analyst says | ||
| 12.12.25 | Arcus halts Gilead-partnered TIGIT trials as biotech reworks R&D focus | ||
| 12.12.25 | Cycle seizes struggling Applied Tx, picking up rare disease biotech for pennies per share | ||
| 11.12.25 | Rezolute's stock plunges 87% after hypoglycemia drug flunks pivotal phase 3 test | ||
| 11.12.25 | Lilly's obesity triple threat smashes efficacy expectations in phase 3 but proves intolerable for some | ||
| 11.12.25 | Moderna taps Nanexa to improve delivery of injectable therapies in back-loaded $500M pact | ||
| 11.12.25 | Zealand pens $2.5B oral cardiometabolic collab with fresh-faced Chinese biotech | ||
| 11.12.25 | GRI touts IPF safety edge, lung function gains amid cash crunch | ||
| 10.12.25 | Apple Tree Partners files for bankruptcy to keep cash flowing to portfolio biotechs |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .